Is Orlistat a Semaglutide? What These Two Medicines Actually Are

You searched both names, here is what you actually found

Imagine you have spent an evening reading about weight-loss options and two names keep appearing: orlistat and semaglutide. They both come up on NHS pages, both are connected to weight management, and at some point the question forms naturally: are they the same thing, or versions of the same thing? The short answer is no, and it is worth being clear about why, because the mechanism behind a medicine shapes who it suits, what side effects to expect, and how it fits into everyday life.

Orlistat works entirely in your digestive tract. It inhibits the enzyme lipase, which your body uses to break down fat from food. When lipase is partly blocked, roughly a third of the fat you eat passes through unabsorbed. It has no effect on appetite. The comparison between orlistat and Wegovy is essentially a comparison between two very different tools designed for the same broad goal.

Semaglutide takes a different route entirely. It mimics GLP-1, a hormone released after eating, which signals fullness to the brain, slows how quickly food leaves the stomach, and influences how much you want to eat in the first place. The result is a meaningful reduction in appetite and calorie intake, without the digestive side effects that come from unabsorbed fat. The mechanism behind semaglutide is worth reading if you want a fuller picture of how GLP-1 agonism works.

What each medicine is licensed for in the UK

Orlistat is licensed in the UK for weight management. At 60mg, it is available without a prescription from a pharmacy. At 120mg (the prescription-strength version, sometimes called Xenical), it requires a GP or prescriber. The NHS notes that it is typically considered alongside dietary changes rather than as a standalone treatment, and there is no NICE technology appraisal for orlistat in the way that exists for the newer GLP-1 medicines.

Semaglutide for weight management is available in the UK as Wegovy, a once-weekly subcutaneous injection. NICE recommended it (in guidance TA875) for use within specialist weight management services, for adults with a BMI of 35 or above and at least one weight-related condition, for a maximum of two years. Private prescribing follows the licensed criteria directly: a BMI of 30 or above, or 27-plus with a qualifying condition such as hypertension or obstructive sleep apnoea. Both routes require clinical assessment by a prescriber, semaglutide is a prescription-only medicine, full stop.

As of summer 2026, an oral version of semaglutide for weight loss (Wegovy tablets) has also received MHRA approval in the UK, making it the first oral GLP-1 medicine licensed here for this purpose. It follows a separate dose escalation schedule and is taken once daily, first thing in the morning before food. You can read more about Wegovy and how it is prescribed across both formats on our treatment overview.

Can orlistat and semaglutide be taken together?

This is where the question gets more clinical. There is no licensed combination product containing both, and combining them is not standard practice. Orlistat affects fat absorption; semaglutide affects appetite and energy intake. In theory they target different pathways, but whether combining them is appropriate for a given person depends entirely on that person's health picture, their other medicines, kidney function, GI history, and how well they are tolerating either drug alone.

The more detailed answer to whether orlistat and Wegovy can be taken together involves understanding the overlapping gastrointestinal side effects both medicines can cause, and why that matters when both are active at once. If you are currently taking orlistat and wondering whether semaglutide is a better or additional option, that is a conversation for a prescriber who can see your full clinical picture, not a decision to make from a search result.

For context on what the private treatment landscape looks like, including how prices are structured across different weight-loss medicines, our Wegovy pricing page explains what a clinically supervised private prescription typically includes. A prescription for a medicine like semaglutide is not simply a purchase; it follows a clinical assessment, and that assessment is what makes the difference between a medicine that helps and one that causes harm.

Which one might be right for you, and how that decision gets made

There is no universal answer here, and any page that offers one is simplifying things to the point of being unhelpful. Orlistat suits some people well, particularly those who respond to a fat-restriction mechanism and whose diet makes the side effects manageable. Semaglutide has produced larger average weight reductions in trials (around 15% over 68 weeks at the 2.4mg dose in the STEP 1 trial, published in the New England Journal of Medicine) and works through appetite rather than fat absorption, which some people find fits better with their day-to-day life.

The NHS medicines pages for both orlistat and semaglutide lay out the licensed uses, typical side effects, and who each medicine is not suitable for. Reading both is a reasonable starting point. The next step is a clinical conversation. If you are considering semaglutide specifically, speaking to our prescribers through a free consultation is how that process starts at nume, no referral, no waiting list, same-day clinical review.